Printer Friendly
The Free Library
14,587,546 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Questcor to Provide Q1 Results.


Conference Call to be held Wednesday, April 30, 2008 at 11am ET

UNION CITY, Calif. -- Questcor Pharmaceuticals, Inc. (AMEX AMEX

See: American Stock Exchange
:QSC QSC Quality Service Communications (Cologne, Germany)
QSC Quilter Sound Company (QSC Audio Products Inc.)
QSC Queens Surface Corporation
QSC Low-Traffic Ship (radiotelegraphy) 
) announced today that it will release financial results for the first quarter of fiscal 2008 ended March 31, 2008, before the market opens on Wednesday, April 30, 2008. The company will host a conference call to discuss these results on Wednesday, April 30, 2008 at 11:00 a.m. ET. During this call the company will discuss it first quarter 2008 results. Don Bailey, President and Chief Executive Officer and Steve Cartt, Executive Vice President, Corporate Development will host the call.

To participate in the live call by telephone, please dial (800) 257-7087 from the U.S. or (303) 262-2140 from outside the U.S. Please use conference ID number 11113031#. Participants are asked to call the above numbers 5-10 minutes prior to the starting time Noun 1. starting time - the time at which something is supposed to begin; "they got an early start"; "she knew from the get-go that he was the man for her"
commencement, get-go, offset, outset, showtime, start, kickoff, beginning, first
. The call will also be webcast live at www.questcor.com. An audio replay of the call will be available for 7 days following the call at (800) 405-2236 for U.S. callers or (303) 590-3000 for those calling outside the U.S. The password required to access the replay is 11113031#. An archived webcast will also be available at www.questcor.com for 90 days.

About Questcor - Questcor Pharmaceuticals, Inc. is a pharmaceutical company that owns two commercial products, H.P. Acthar([R]) Gel ("Acthar") and Doral([R]) , and is developing new medications using strategies that generally require lower capital investment when compared to traditional development programs. Acthar (repository corticotropin corticotropin (kôr'təkōtrōp`ən): see adrenocorticotropic hormone.  injection) is an injectable in·ject·a·ble
adj.
Capable of being injected. Used of a drug.

n.
A drug or medicine that can be injected.
 drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS"). In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome Opsoclonus myoclonus syndrome (OMS) is a rare neurological disorder of unknown causes which appears to be the result of an autoimmune process involving the nervous system. It is an extremely rare condition, affecting as few as 1 in 10,000,000 people per year. , a rare autoimmune-related childhood neurological disorder. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The Company is also developing new medications, including QSC-001, a unique orally disintegrating tablet The Food and Drug Administration's (FDA) definition of an orally disintegrating tablet (ODT) is: "A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue.  formulation of hydrocodone bitartrate and acetaminophen hydrocodone bitartrate and acetaminophen Warning - High-alert drug!

Anexsia, Ceta-Plus, Co-Gesic, Hydrocet, Lorcet-HD, Lortab, Vicodin, Vicodin HP

Pharmacologic class:
 for the treatment of moderate to moderately severe pain. For more information, please visit www.questcor.com.
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Financial report
Date:Apr 22, 2008
Words:378
Previous Article:Pegasystems Receives 2008 CRM Excellence Award from Customer Interaction Solutions Magazine.(Company overview)
Next Article:TRADE NEWS: Agilent Technologies Announces Expanded RF/Mixed-Signal Simulation Coverage for Wireless Communications IC Design.



Related Articles
Dutton & Associates Announces Investment Opinion: Questcor Rating of Strong Buy Maintained By Dutton & Associates.
J.M. Dutton & Associates Announces Investment Opinion: Questcor Rating Lowered to Neutral by Dutton & Associates in Continuing Coverage.
Questcor Announces Financial Results for 2006 Second Quarter; Sales of Acthar Gel Exceed $3 Million; 60% Increase Over First Quarter 2006.
Questcor Announces Departure of CEO James Fares.
Questcor Announces Financial Results for 2007 Second Quarter.(Financial report)
Questcor Board Approves New Strategy and Business Model for H.P. Acthar Gel.
Questcor Provides Progress Report on New H.P. Acthar Gel Strategy.
Questcor Reports Third Quarter Results.(Financial report)
Questcor Appoints Stephen Farrell to Board of Directors.
Questcor Reports Strong First Quarter 2008 Results.(Financial report)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles